Therapeutic impact of rHuEPO on abnormal platelet APP, BACE 1, presenilin 1, ADAM 10 and A β expressions in chronic kidney disease patients with cognitive dysfunction like Alzheimer’s disease: A pilot study
Conclusions This study demonstrated that rHuEPO is an effective neuroprotective agent in the context of CKD associated cognitive dysfunction and proved its clinical usefulness. Graphical abstract
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
More News: Anemia | Brain | Chronic Kidney Disease | Drugs & Pharmacology | Neurology | Normocytic Normochromic Anemia | Statistics | Study | Urology & Nephrology